Ruten

Ruten Therapeutics is a pre-clinical stage biotechnology company focused on the development of small molecule therapeutics that target O-GlcNAcylation, a critical post-translational modification. The company leverages a proprietary platform to modulate the enzymes O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), which regulate the addition and removal of sugar molecules on intracellular proteins. Dysregulation of O-GlcNAc signaling is a key driver in various diseases, particularly in oncology and neurodegeneration. Ruten's approach aims to address these conditions by restoring protein homeostasis and metabolic signaling through highly selective chemical inhibitors and activators. Founded by experts in chemical biology and backed by specialized life science investors, the company is advancing a pipeline of novel candidates toward clinical development.